Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
copy from BMJ
Interferon ß 1a (SNG001)
SNG001 is an inhaled formulation of a drug called interferon ß—a molecule that forms part of the lung’s own defence mechanism to fight off viruses. It has been tested in phase two trials for asthma patients and was found to lead to improvements in lung function. In covid-19, the theory has been raised that SNG001 could work by increasing the production of INF-ß—thought to be suppressed by coronaviruses—to prevent or decrease symptoms of severe respiratory illness, such as pneumonia.
In the UK, pharmaceutical company Synairgen has been given expedited approval from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority to test the drug for patients with covid-19 in a clinical trial.
Ian Hall, professor of molecular medicine at the University of Nottingham, said, “The idea behind the trial is that by giving more of this molecule to the lung it could help reduce the severity of infection with covid-19, especially in those people who have reduced immune responses to the virus. If the trial shows that interferon beta is a useful treatment for covid-19, it would provide a way to reduce the severity of disease and potentially reduce death rates.”
Along with Faron and Tanzia life but Synairgen could be more likely in the first instance
https://www.dailymail.co.uk/money/investing/article-8143275/SMALL-CAP-SHARE-IDEAS-AIM-trio-wade-battle-against-coronavirus-lung-disease.html